Treatment of systemic fungal infections: Recent progress and current problems

European Journal of Clinical Microbiology & Infectious Diseases

Volumn 7, Issue 4, 1988, Pages 460-475

  Walsh, T J ^a   Pizzo, A ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; RIFAMPICIN;

ADVERSE DRUG REACTION; DRUG SENSITIVITY; FUNGEMIA; FUNGUS; HOST RESISTANCE; HUMAN; MYCOSIS; REVIEW; SYSTEMIC MYCOSIS;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CHEMISTRY; FLUCONAZOLE; FLUCYTOSINE; HUMAN; ITRACONAZOLE; KETOCONAZOLE; MICONAZOLE; MYCOSES; TRIAZOLES;

EID: 0023752762     PISSN: 09349723     EISSN: 14354373     Source Type: Journal    
DOI: 10.1007/BF01962595     Document Type: Review

References (164)

1. Fungemia in a cancer hospital: changing frequency, earlier onset, and results of therapy
2. Nosocomial fungal infections
3. Cryptococcosis in the acquired immune deficiency syndrome
4. Amphotericin B pharmacokinetics in humans
5. Flucytosine and amphotericin B: hemodialysis effects on the plasma concentration and clearance
6. Excretion pathways of amphotericin B
7. Pharmacokinetics of amphotericin B in infants and children
8. Penetration of amphotericin B into the human eye
9. The influence of sodium status and furosemide on canine acute amphotericin B nephrotoxicity
10. Amphotericin B nephrotoxicity in humans decreased by salt repletion
11. Sodium depletion enhances nephrotoxicity of amphotericin B
12. Renal magnesium wasting associated with amphotericin B therapy
13. Risk factors of ventricular fibrillation during amphotericin B infusion
14. Acute renal toxicity with combined use of amphotericin B and cyclosporine after marrow transplantation
15. Lethal pulmonary reactions associated with the combined use of amphotericin B and leukocyte transfusions
16. Amphotericin B promotes leukocyte aggregation of nylon wool-fiber-treated polymorphonuclear leukocytes
17. Liposomal amphotericin B is toxic to fungal cells but not to mammalian cells
18. Liposomal amphotericin B for the treatment of systemic fungal infections in patients with cancer: a preliminary study
19. Treatment of hepatosplenic candidiasis with liposomal amphotericin B
20. Fungemia in the immunocompromised host
21. Empirical antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia
22. Fungal infections in patients with acute leukemia
23. Empiric amphotericin B therapy in patients with acute leukemia
24. Clinical value of amphotericin B in patients with acute myelogenous leukemia
25. Can antibacterial therapy be discontinued in persistently febrile granulocytopenic cancer patients?
26. Diagnosis and treatment of fungal infections in patients with hematologic malignancies
27. Incidence of polyene-resistant yeasts recovered from clinical specimens
28. Fatal disseminated candidiasis due to amphotericin B — resistant Candida guillermondi
29. Development of amphoteri-in B-resistant Candida tropicalis in a patient with defective leukocyte function
30. Fatal septicemia due to amphotericin B-resistant Candida lusitaniae
31. Isolation and characterization of a polyene-resistant variant of Candida tropicalis
32. Development of resistance to amphotericin B in Candida lusitaniae infection a human
33. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis
34. Granulomatous hepatitis due to Candida albicans in patients with acute leukemia
35. Computed tomography of hepatic and splenic fungal abscesses in leukemic children
36. Candidiasis of the liver and spleen
37. Focal hepatic candidiasis: a distinct clinical variant of candidiasis in immunocompromised patients
38. Hepatic candidiasis in cancer patients
39. Candidial splenic abscesses complicating acute leukemia of childhood treated by splenectomy
40. Distribution and activity of amphotericin B in humans
41. Interaction of plasma proteins and lipoproteins with amphotericin B
42. Postoperative fungal endocarditis
43. Infections associated with intravascular lines
44. Nosocomial fungemia in neonates associated with intravascular pressure-monitoring devies
45. Persistence of Candida despite seemingly adequate systemic and intraperitoneal amphotericin B treatment in a patient on CAPD
46. Fungal peritonitis in patients receiving peritoneal dialysis: experience with 11 patients and review of the literature
47. Fungal peritonitis in children undergoing peritoneal dialysis
48. Ventriculoatrial shunt infection due to Cryptococcus neoformans: an ultrastructural and quantitative microbiologic study
49. Candidal suppurative peripheral thrombophlebitis: recognition, prevention, and management
50. Malassezia fungemia in neonates and adults: complication of hyperalimentation
51. Systemic Malassezia furfur infection in patients receiving intralipid therapy
52. Malassezia pulmonary vasculitis in an infant on long-term intralipid therapy
53. Cryptococcal disease in patients with the acquired immune deficiency syndrome
54. Trichosporon beigelli infection: a review
55. Trichosporonosis in patients with neoplastic diseases
56. Metastatic fungal chorioretinitis developing during Trichosporon sepsis
57. Fusarium. A newly recognized fungal pathogen in immunosuppressed patients
58. Invasive Fusarium infections in bone marrow transplant recipients
59. Fungemia due to Fusarium solani in an immunocompromised child
60. Catheter-associated fungemia caused by Fusarium chlamydosporum in a patient with lymphocytice lymphoma
61. Pheaohyphomycosis
62. Comparative histopathology of Dactylaria constricta, Fonsecaea pedrosoi, Wagiella dermatitidis, and Xylohypha bantiana in experimental phaeohyphomycosis of the central nervous system
63. Experimental therapy of cladosporiosis and sporotrichosis with 5-fluorocytosine
64. In vitro and in vivo drug studies with three agents of central nervous system phaeohyphomycosis
65. Infectious due to Wangiella dermatitidis in humans: report of the first documented case from the United States and a review of the literature
66. Phaeohyphomycosis caused by the fungal genera Bipolaris and Exserohilum. A report of 9 cases and review of the literature
67. Combined effect of amphotericin B and rifampin on Candida species
68. Combined in vitro effect of amphotericin B and rifampin on Cryptoccus neoformans
69. Antifungal action of rifampin
70. Activity of amphotericin B, 5-fluorocytosine and rifampin against six clinical isolates of Aspergillus
71. Enhanced efficacy of amphotericin B and rifampicin in treatment of murine histoplasmosis and blastomycosis
72. Therapy of murine aspergillosis with amphotericin B in combination with rifampin or 5-fluorocytosine
73. Interaction of rifampin with other antifungal agents in experimental murine candidiasis
74. Combination antifungal chemotherapy for experimental disseminated candidiasis: lack of correlation between in vitro and in vivo observations with amphotericin B and rifampin
75. Combined activity of minocycline and amphotericin B in vitro against medically important yeasts
76. In vitro studies of amphotericin B in combination with the imidazole antifungal compounds and miconazole
77. The effect of ketoconazole on amphotericin B in a model of disseminated aspergillosis
78. Effect of ketoconzaole on the fungicidal action of amphotericin B in Candida albicans
79. Combination therapy of experimental histoplasmosis and cryptococcosis with amphotericin B and ketoconazole
80. Flucytosine kinetics in subjects with normal renal function
81. Rapid, simple bioassay for 5-fluorocytosine in the presence of amphotericin B
82. Simple assay for 5-fluorocytosine in the presence of amphotericin B
83. Simplified bioassay method for measurement of flucytosine or ketoconazole
84. Gas chromatographic determination of 5-fluorocytosine in human serum
85. High performance liquid chromatography and other nonbiological methods for the quantitation of antifungal drugs
86. Rapid determination of 5-fluorocytosine levels in blood
87. Mode of action of 5-fluorocytosine
88. Evidence for conversion of 5-fluorocytosine to 5-fluorouracil in humans. Possible factor in 5-fluorocytosine clinical toxicity
89. Bone marrow toxicity associated with 5-fluorocytosine therapy
90. Toxicity of amphotericin B plus flucytosine in 194 patients with cryptococcal meningitis
91. A comparison of amphotericin B alone and in combination with flucytosine in the treatment of cryptococcal meningitis
92. Cryptococcal intracerebral mass lesions: the role of computer tomography and nonsurgical management
93. Synergism of amphotericin B and 5-fluorocytosine for Candida species
94. Combination therapy of experimental candidiasis and aspergillosis in mice
95. An experimental model of candidiasis in rabbits with prolonged neutropenia: its evaluation of single drug and combination antifungal therapy
96. Synergism of polyene antibiotics with 5-fluorocytosine
97. Synergistic action of amphotericin B and flucytosine against yeast-like organisms
98. Combined therapy with amphotericin B and flucytosine for Candida meningitis
99. Favorable outcome of invasive aspergillosis in patients with acute leukemia
100. Miconazole in cryptococcosis and systemic candidiasis: a word of caution
101. Systemic pseudallescheriasis in a patient with acute myelocytic leukemia
102. Clinical significance of Pseudallescheria boydii. A review of ten years experience
103. Pseudallescheria boydii in a patient with acute lymphoblastic leukemia
104. Pseudallescheria boydii infection of the central nervous system in a cardiac transplant recipient
105. Brain abscess due to Pseudallescheria boydii associated with primary non-Hodgkin's lymphoma of the central nervous system: a case report and literature review
106. Visceral fungal infections due to Petriellidium boydii (Allescheria boydii). In vitro drug sensitivity studies
107. Deep infections from Petriellidium boydii treated with miconazole
108. Successful medical treatment of pulmonary petriellidiosis
109. Pseudallescheria boydii infections treated with ketoconazole: clinical evaluations of seven patients and in vitro susceptibility tests
110. Miconazole in the treatment of systemic fungal infections
111. Ketoconazole: a review of its therapeutic efficacy in superficial and systemic fungal infections
112. Influence of food on the pharmacokinetics of ketoconazole
113. Treatment of systemic mycosewith ketoconazole: in vitro susceptibilities of clinical isolates of systemic and pathogenic fungi to ketoconazole
114. Treatment of blastomycosis and histoplasmosis with ketoconazole
115. Disposition of ketoconazole, an oral antifungal in humans
116. Interaction of ketoconazole with rifampin and isoniazid
117. Ketoconazole, cyclosporin metabolism and renal transplantation
118. Ketoconazole and cyclosporin
119. Cyclosporin-ketoconazole: a potentially dangerous drug interaction
120. Interaction of cyclosporin A and ketoconazole
121. Treatment of systemic mycoses with ketoconazole emphasis on toxicity and clinical response in 52 patients. National Institute of Allergy and Infectious Disease collaborative antifungal study
122. Fatal hepatitis associated with ketoconazole therapy
123. Hepatic reactions during ketoconazole treatment
124. Hepatic injury associated with ketoconazole therapy: analysis of 33 cases
125. The use of ketoconazole as an inhibitor of steroid production
126. Ketoconazole blocks adrenal steroid synthesis
127. Ketoconazole blocks testosterone synthesis
128. Ketoconazole inhibition of testicular secretion of testosterone and displacement of steroid hormones from serum transport proteins
129. Ketoconazole blocks adrenal steroidogenesis by inhibiting cytochrome P450-dependent enzymes
130. Persistent adrenal insufficiency secondary to low-dose ketoconazole therapy
131. Non-suppression of cortisol secretion by long-term treatment with ketoconazole in patients with acute leukemia
132. Reversible adrenal insufficiency induced by ketoconazole
133. Treatment of paracoccidioidomycosis with ketoconazole a three year experience
134. Post-therapy status of paracoccidioidomycosis treated with ketoconazole
135. Treatment of blastomycosis and histoplasmosis with ketoconazole
136. Systemic blastomycosis in children
137. Ketoconazole for treatment of disseminated coccidioidomycosis
138. Ketoconazole treatment of nonprimary coccidioidomycosis. Evaluation of 60 patients during three years of study
139. Primary cutaneous coccidioidomycosis in children
140. Experience with ketoconazole in three major manifestations of progressive coccidioidomycosis
141. Ketoconazole for systemic fungal infections. Inadequacy of standard dose regimens
142. Histoplasmosis cooperative study. V: Amphotericin B dosage for chronic pulmonary histoplasmosis
143. High-dose ketoconazole for treatment of fungal infections of the central nervous system
144. Amphotericin B or ketoconazole therapy of fungal infection in neutropenic cancer patients
145. Cutaneous ocular and osteoarticular candidiasis in heroin addicts: new clinical and therapeutic aspects in 38 patients
146. Azole antifungal agents: emphasis on new triazoles
147. Itraconazole: pharmacologic studies in animals and humans
148. Itraconazole in the treatment of paracoccidioidomycosis: a preliminary report
149. Oral treatment of paracoccidioidomycosis and histoplasmosis with itraconazole in humans
150. A clinical trial of itraconazole in the treatment of deep mycoses and leishmaniasis
151. Itraconazole (R 51-211): a clinical review of its antimycotic activity in dermatology, gynecology, and internal medicine
152. Tolerance to and efficacy of itraconazole in treatment of systemic mycoses: preliminary results
153. Initial experience in therapy for progressive mycoses with itraconazole, the first clinically studied triazole
154. Early experience with itraconazole in vitro and in patients: pharmacokinetic studies and clinical results
155. Antifungal effects of fluconazole (UK49858), a new triazole antifungal, in vitro
156. Pharmacokinetic evaluation of UK-49, 858, a metabolically stable triazole antifungal drug, in animals and humans
157. Comparison of itraconazole and fluconazole in treatment of cryptococcal meningitis and candida pyelonephritis in rabbits
158. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system
159. Cryptococcal meningitis and fluconazole
160. Cryptococcal meningitis in the acquired immune deficiency syndrome (AIDS): successful treatment with fluconazole after failure of amphotericin B
161. Disseminated histoplasmosis in patients with the acquired immune deficiency syndrome
162. Disseminated histoplasmosis associated with the acquired immune deficiency syndrome
163. Histoplasmosis in the acquired immune deficiency syndrome
164. Coccidioidomycosis in the acquired immune deficiency syndrome